How daraxonrasib is reshaping cancer care

Advertisement

When the FDA approved daraxonrasib for metastatic pancreatic cancer Aug. 26, some in oncology expected access to remain concentrated at academic medical centers. Nearly three months later, leaders at seven organizations say patients at many cancer centers, including community sites, are starting the drug within one to two weeks.

Instead, the remaining access barriers have proven to be largely administrative. The drug’s rollout is changing outpatient workflows and raising questions about specialty pharmacy strategy, referrals and treatment sequencing.

Becker’s spoke with leaders from Philadelphia-based Penn Medicine, the University of Miami’s Sylvester Comprehensive Cancer Center, University of California San Diego Health, Madison, Wis.-based UW Health Carbone Cancer Center, Philadelphia-based Jefferson Health, Cleveland-based University Hospitals and Lowell (Mass.) General Hospital about the early lessons from daraxonrasib’s rollout.

Access is improving, but administrative barriers remain

At Moores Cancer Center at UC San Diego Health, an eligible patient already in the system can now go from the decision to treat to a first dose in about five to seven days, according to Gregory Botta, MD, PhD, a gastrointestinal medical oncologist there. 

At UW Health, the wait has dropped from 10 to 14 days at launch to just three to seven days, Elizabeth Dow-Hillgartner, PharmD, a clinical pharmacist at the Carbone Cancer Center, told Becker’s. Penn Medicine, Sylvester and University Hospitals leaders each reported treatment starts within one to two weeks.

“It is taking three to four weeks to get the drug for us in the community,” Anasuya Gunturi, MD, PhD, chief of oncology at Lowell General Hospital, part of Burlington, Mass.-based Tufts Medicine, said. “The biggest bottleneck is getting insurance approval.”

Penn Medicine opened its expanded access program at two community locations before FDA approval. At UW Health, some patients initially traveled from smaller community practices to begin treatment before returning to their local oncologists, with communication continuing between care teams.

“You need a team of people working on prior authorizations for this medication,” Dr. Dow-Hillgartner told Becker’s. “To date, I’ve gotten everybody on the drug.” Medicare approvals have moved quickly, she said, while some commercial payers have required appeal letters from oncologists.

Because copays vary widely, Penn’s team applies for the manufacturer’s assistance program when the drug is ordered, rather than waiting to see the bill, Kim Reiss, MD, a pancreatic cancer specialist at Penn Medicine’s Abramson Cancer Center, told Becker’s.

A different kind of outpatient workload

Daraxonrasib’s side effects, mainly rash, mouth sores and diarrhea, can be harder on some patients than chemotherapy. Steven Cohen, MD, who leads the gastrointestinal oncology group at Jefferson Health, estimated that a third or more of patients need a dose reduction.

Managing daraxonrasib’s side effects can require frequent office visits, lab work, nurse triage and telehealth. Dr. Cohen said patients may need weekly visits early in treatment, along with close coordination among oncologists, nurses, advanced practice providers and pharmacists. UW Health also refers patients with harder-to-manage rashes to an oncology dermatologist.

“You can’t just write a script and say all right, I’ll see you next month,” Dr. Cohen said.

David Bajor, MD, gastrointestinal disease team leader at University Hospitals Seidman Cancer Center, said most side effects can be managed through outpatient visits, telehealth or supportive treatments such as IV fluids. Because daraxonrasib does not cause the neutropenic fever that often sends chemotherapy patients to the hospital, he expects hospitalizations could decline as more patients move to RAS inhibitors. 

Why specialty pharmacy matters

Daraxonrasib launched through a limited distribution network of two specialty pharmacies, Onco360 and Biologics by McKesson.

“Having hospital-based specialty pharmacies being able to dispense would substantially expedite and streamline access,” said Peter Hosein, MD, a medical oncologist and associate director for clinical research at Sylvester’s Pancreatic Cancer Research Institute.

Dr. Dow-Hillgartner said Revolution Medicines has indicated it will open distribution to more specialty pharmacies. Once UW Health’s in-house specialty pharmacy can dispense the drug, she expects patients to start treatment much faster.

What happens when the drug stops working

Resistance develops after roughly seven months in nearly every patient treated with daraxonrasib. Once patients stop responding to treatment, they have few options outside of starting a new chemotherapy regimen or enrolling in a clinical trial. 

“It means the gap between an academic center and a community practice is no longer about access to daraxonrasib itself,” Dr. Botta said. “It is about what happens eight to twelve months later when the drug stops working.”

He recommends connecting patients treated in community settings with an academic center when they start daraxonrasib, rather than waiting until their disease progresses. Patients may be too ill to travel or participate in a trial by the time they need another treatment, he said.

Dr. Gunturi said Lowell General refers patients to academic centers for clinical trials, but transportation, parking and time off can make participation difficult.

Community oncologists have managed targeted therapies for lung and breast cancer for years, Dr. Bajor said, and he expects daraxonrasib could allow them to treat pancreatic cancer patients locally for longer. He questioned whether that could ultimately reduce referrals to academic centers and the number of patients available for clinical trials.

“You don’t need to see the big shots in the city,” he said. “We can take care of you here for a lot longer.”

Why molecular testing matters earlier

Daraxonrasib is a RAS inhibitor, a class of drugs that block the RAS proteins that drive tumor growth when mutated. According to the National Cancer Institute, mutated RAS proteins are present in about 90% of pancreatic tumors. Daraxonrasib blocks several forms of RAS at once, while newer RAS inhibitors in development target a single mutation.

Dr. Bajor said mutation-specific drugs such as zoldonrasib could become the first choice for some patients as soon as next year, with daraxonrasib reserved for later treatment.

Knowing a patient’s specific RAS mutation before starting treatment is important, Dr. Botta told Becker’s, because daraxonrasib treatment could affect future eligibility for mutation-specific inhibitor trials. He recommends completing molecular testing at diagnosis rather than waiting until patients need another treatment.

“If a community oncologist orders comprehensive tumor [next-generation sequencing], germline testing, and tumor-informed [circulating tumor DNA] at diagnosis, that patient is functionally trial-ready wherever they live,” Dr. Botta said.

Preparing for the next wave of RAS inhibitors

Dr. Botta expects daraxonrasib to be the first of several RAS-targeted therapies to reach cancer patients over the next several years.

To prepare, he recommends that payers, specialty pharmacies and manufacturers agree on a 72-hour authorization standard for oral cancer drugs such as daraxonrasib. Health systems should also consider pharmacist-led oral oncology programs and nurse navigators who manage the handoff from prescription to pharmacy to patient, he said.

Dr. Bajor credited University Hospitals’ investigational pharmacy with ensuring patients in the expanded access program did not miss a dose. He expects that kind of pharmacy expertise to matter more as additional RAS inhibitors are approved and oncologists must decide which drug patients receive first.

At UW Health, Dr. Dow-Hillgartner began coordinating the development of electronic treatment plans within a day of daraxonrasib’s approval and has led much of the staff education on the drug. Dr. Reiss said community providers will need similar education and real-time consultation on managing side effects as more RAS inhibitors reach the market.

“The infrastructure we build now at UC San Diego and across health systems will determine whether each subsequent approval is a repeat of the scramble we lived through this summer or a routine, same-week start,” Dr. Botta said.

At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.

Advertisement

Next Up in Pharmacy

Advertisement